SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies

Breast cancer highlights from ASCO 2019

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer

Better education about breast cancer treatment in Africa

Genomic trends across the African Diaspora for breast cancer

Highlights from ASCO 2019

Potential of PARP inhibitors for metastatic breast cancer

PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer

Treating ovarian cancer patients with PARP inhibitors